メタ情報
| meta description平均長 | 264 |
|---|
| OGPありページ数 | 16 |
|---|
| Twitterカードありページ数 | 0 |
|---|
内部リンク分析（Internal）
| ユニーク内部リンク数 | 93 |
|---|
| ページあたり内部リンク平均 | 102.62 |
|---|
連絡先候補（Contacts）
このデータの閲覧には会員登録が必要になります。会員登録
キーワード分析（KeywordMap）
ワードクラウド上位
| 語 | 重み |
|---|
| cell | 1 |
| cells | 0.889414 |
| UltraGRO | 0.883369 |
| MSCs | 0.824478 |
| PURE | 0.795032 |
| development | 0.782235 |
| products | 0.711123 |
| Exosome | 0.706695 |
| Depleted | 0.706695 |
| AventaCell | 0.691766 |
| expansion | 0.642354 |
| MSC | 0.588913 |
| platelet | 0.543531 |
| serum | 0.530021 |
| Scalable | 0.530021 |
| stem | 0.47113 |
| filings | 0.47113 |
| Learn | 0.47113 |
| more | 0.47113 |
| human | 0.458333 |
| lysate | 0.444707 |
| used | 0.441684 |
| tissue | 0.441684 |
| immune | 0.441684 |
| production | 0.426674 |
| research | 0.426674 |
| manufacturing | 0.426674 |
| culture | 0.416667 |
| our | 0.355561 |
| applications | 0.355561 |
| clinical | 0.353348 |
| have | 0.353348 |
| PRT | 0.353348 |
| Silva | 0.353348 |
| Milligan | 0.353348 |
| Mesenchymal | 0.353348 |
| therapy | 0.353348 |
| Helios | 0.353348 |
| Bioscience | 0.353348 |
| ISCT | 0.353348 |
| Conference | 0.353348 |
| business | 0.353348 |
| Cambium | 0.353348 |
| superior | 0.353348 |
| doi | 0.353348 |
| hPL | 0.345883 |
| efficient | 0.294456 |
| pathogen | 0.284449 |
| derived | 0.284449 |
| based | 0.284449 |
共起語上位
| 語1 | 語2 | スコア | 共起ページ数 |
|---|
| PURE | UltraGRO | 3.108268 | 36 |
| Depleted | Exosome | 2.985365 | 24 |
| lysate | platelet | 2.912123 | 36 |
| Learn | more | 2.351106 | 13 |
| Manufacturing | Scalable | 2.324037 | 14 |
| reduction | treatment | 2.30723 | 12 |
| BioMedical | Corp | 2.30723 | 12 |
| Bioscience | Helios | 2.30723 | 12 |
| Business | Continuity | 2.143833 | 8 |
| pathogen | reduction | 2.141101 | 12 |
| PRT | treatment | 2.141101 | 12 |
| Lobato | Silva | 2.141101 | 12 |
| Depleted | UltraGRO | 2.105849 | 20 |
| Business | COVID | 2.090442 | 8 |
| Meet | filings | 2.038445 | 10 |
| filings | regulatory | 2.038445 | 10 |
| filings | requirements | 2.038445 | 10 |
| CMC | filings | 2.038445 | 10 |
| Continuity | Statement | 2.023692 | 7 |
| Free | Xeno | 1.994921 | 8 |
| Free | Safe | 1.994921 | 8 |
| Production | Supplement | 1.994921 | 8 |
| State | art | 1.994921 | 8 |
| art | gamma | 1.994921 | 8 |
| gamma | irradiation | 1.994921 | 8 |
| inactivation | viral | 1.994921 | 8 |
| Regulatory | bioreactors | 1.994921 | 8 |
| Meet | regulatory | 1.994921 | 8 |
| regulatory | requirements | 1.994921 | 8 |
| CMC | requirements | 1.994921 | 8 |
| developing | novel | 1.994921 | 8 |
| See | You | 1.994921 | 8 |
| Paris | Virtual | 1.994921 | 8 |
| Medical | Technologies | 1.994921 | 8 |
| incorporate | strategies | 1.994921 | 8 |
| milieu | richer | 1.994921 | 8 |
| grow | milieu | 1.994921 | 8 |
| differentiate | into | 1.994921 | 8 |
| cord | umbilical | 1.994921 | 8 |
| valuable | viable | 1.994921 | 8 |
| Pinto | Sousa | 1.994921 | 8 |
| Claudia | Silva | 1.986688 | 11 |
| Business | Statement | 1.974517 | 7 |
| COVID | Continuity | 1.918767 | 7 |
| irradiation | process | 1.811122 | 8 |
| 3D | using | 1.811122 | 8 |
| ISCT | You | 1.811122 | 8 |
| ISCT | Paris | 1.811122 | 8 |
| Conference | Virtual | 1.811122 | 8 |
| provide | richer | 1.781616 | 7 |